AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02214381
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04100083
Drug: Spironolactone 100mg
RxNorm normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Trial: NCT04100083
Drug: Spironolactone 200 mg
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study visit timeline: initial visit \[consent and enrollment followed by baseline exam (0 months), 3 months, 6 months, and follow up at 7 months, with optional treatment extension period for up to one year of total treatment during which patients will follow up every 3 months~The drug will be taken via oral tablets once daily for a duration of 6 months. Patients will be instructed to continue any current treatment regimen for hidradenitis suppurativa that was initiated at least 4 weeks prior to their enrollment in the study. Patients will be instructed to avoid potassium supplements and foods containing high levels of potassium, including salt substitutes, which could potentially lead to hyperkalemia. They will be instructed to avoid medications listed in the exclusion criteria.
Trial: NCT02903121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
Trial: NCT03363854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Trial: NCT01430520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
Trial: NCT03611153
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single administration dose of 30 mg placebo given orally following baseline, resting and exercise testing in patients during right heart catheterization.
Trial: NCT03837977
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm I
Trial: NCT03316898
Drug: AGN-242071
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
Trial: NCT03316898
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
Trial: NCT03147612
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03147612
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intrathecally or IV
Trial: NCT00406250
Drug: intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg in 0.05 cc of bevacizumab
Trial: NCT00406250
Drug: intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg of bevacizumab intravitreally injected in a steril field
Trial: NCT01070511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
Trial: NCT01254136
Drug: INCB007839 300mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
Trial: NCT03283813
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
Trial: NCT03283813
Drug: Myoinositol
RxNorm normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
Trial: NCT03727802
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single and multiple doses (4 weeks)
Trial: NCT03377543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81mg non-active pill that looks like aspirin
Trial: NCT04429542
Drug: BCA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGFR/TGFβ fusion monoclonal antibody
Trial: NCT00278213
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02260791
Drug: Humira®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
Trial: NCT00078715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
Trial: NCT01689935
Drug: 20 % Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical medication for ALA-PDT and i-PDT
Trial: NCT00719693
Drug: ABT-143 ( rosuvastatin calcium and fenofibric acid )
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose under low-fat meal condition
Trial: NCT00719693
Drug: ABT-143 (rosuvastatin calcium and fenofibric acid )
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one dose under fasting meal condition
Trial: NCT01612494
Drug: Hypertonic Saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
Trial: NCT02205229
Drug: Multi-ingredient, topical compounded medications
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03729128
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.
Trial: NCT04460352
Drug: Oxaliplatin, calcium folinate, 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX: Oxaliplatin 85 mg/m2, calcium folinate 200 mg/m2 and 5-fluorouracil 400 mg/m2 on the first days of weeks 1, 3 and 5 + 5-fluorouracil 800 mg/m2 by continuous infusion on the first two days of weeks 1, 3 and 5.
Trial: NCT02715115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavored solution and Water for Injection
Trial: NCT00561964
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group: 2 placebo capsules daily as a single morning intake
Trial: NCT00630942
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg capsules twice a day before breakfast and before dinner.
Trial: NCT01494727
Drug: Novartis Exforge 10/160mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose
Trial: NCT02143414
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT02143414
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02143414
Drug: Methotrexate Sodium
RxNorm normalized name: Methotrexate Sodium
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02491684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for once daily inhalation for 14 days
Trial: NCT04432454
Drug: Lasofoxifene and abemaciclib (VERZENIO (R)).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lasofoxifene 5 mg given once a day orally and abemaciclib 150 mg given twice a day orally.
Trial: NCT00598585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills 3X/day for 6 weeks
Trial: NCT00902122
Drug: p53 gene therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
Trial: NCT03160118
Drug: Seasonal,quadrivalent,influenza vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose to be administered on Day 0, the first visit
Trial: NCT00846885
Drug: Imitrex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Tablet
Trial: NCT02616523
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
Trial: NCT02178553
Drug: Epidural
RxNorm normalized name: Epidural 17g 3.5"
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02185209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Place capsule to mimic antibiotics
Trial: NCT00641771
Drug: Comparator: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
Trial: NCT03631602
Drug: antifungal prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: posaconazole oral suspension vs itraconazole oral solution
Trial: NCT04524949
Drug: IMCY-0098 450 μg
RxNorm normalized name: urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small synthetic peptide for SC admin. Solvent: alum hydroxide
Trial: NCT04524949
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solvent: alum hydroxide
Trial: NCT02946580
Drug: MOVANTIK™ (naloxegol)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00135694
Drug: calcineurin inhibitor-based immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: May be cyclosporine, mycophenolate mofetil, or tacrolimus
Trial: NCT00135694
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month course of corticosteroids
Trial: NCT02000674
Drug: Succinylcholine : 1mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03851835
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six doses of oral placebo (0.15mg/kg) to be administered q8h (every 8 hours) to a maximum of 3 times in a 24 hour period, are provided to the participant/caregiver for use after emergency department disposition (i.e. home use).
Trial: NCT02735863
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg or 150mg once daily for 28 days
Trial: NCT02735863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 matching placebo
Trial: NCT03059069
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients maintain their medication with either Gliatamin or placebo for 6 months.
Trial: NCT01359319
Drug: Sialic Acid Extended Release (SA-ER) Tables
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
Trial: NCT03580707
Drug: BRV vs LEV in randomized double blinded, crossover fashion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intravenous administration of BRV 100 mg over a 15 minutes period. On a subsequent occasion, (approximately 2 weeks later), the patient is crossed over to the other drug at a singular dose. On both occasions, intermittent photic stimulation is done 10 times in a two hour period. IPS is again conducted in the cross over portion as well. Coincident with IPS stimulation 10 blood samples will be drawn for BRV or LEV plasma concentration.
Trial: NCT02114346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01038609
Drug: Hydrocodone/Acetaminophen Extended Release
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01038609
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01927744
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
Trial: NCT00267267
Drug: ezetimibe/simvastatin
RxNorm normalized name: EZETIMIBE/SIMVASTATIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01871428
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching aleglitazar placebo orally daily
Trial: NCT01314261
Drug: ABT-267
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg or 25 mg tablets
Trial: NCT00173472
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01780311
Drug: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00656981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
Trial: NCT00328939
Drug: ARIXTRA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00142155
Drug: monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04206553
Drug: Oral corticosteroids (OCS)
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone or prednisolone per standard of care to obtain control of disease activity.
Trial: NCT00567398
Drug: Dianeal
RxNorm normalized name: Dianeal PD-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
Trial: NCT00567398
Drug: Physioneal
RxNorm normalized name: Physioneal 40 with 1.36% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physioneal 40 or Physioneal 35
Trial: NCT01143818
Drug: AndroGel (testosterone gel) 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
Trial: NCT01756209
Drug: Ibuprofen 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 10 mg/kg oral single dose
Trial: NCT01756209
Drug: acetaminophen 15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 15 mg/kg oral single dose
Trial: NCT00689728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a single IV infusion over 30 minutes.
Trial: NCT02892357
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Qinghua granules:twice a day,1 bag a time;10mg omeprazole and 10mg sham ,once a day,all for 4 weeks.
Trial: NCT02892357
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sham Jianpi Qinghua granules:twice a day,1 bag a time; 20mg omeprazole once a day ,all for 4 weeks.
Trial: NCT03575052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, tablets, once daily by mouth (provided as two placebo tablets)
Trial: NCT04233112
Drug: Melatonin 5 mg
RxNorm normalized name: melatonin 5 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Trial: NCT04233112
Drug: Placebo (plant fiber) for melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Trial: NCT04069689
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match EPX-100
Trial: NCT03576456
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive placebo prior to angio
Trial: NCT02715609
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00193856
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
Trial: NCT00106496
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT00106496
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical
Trial: NCT00982800
Drug: Placebo Sugar Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00715780
Drug: soluble human insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Trial: NCT00715780
Drug: insulin NPH
RxNorm normalized name: insulin NPH human isophane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Trial: NCT01607957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Trial: NCT02201108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet, Route of administration: oral
Trial: NCT03535727
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO twice daily (BID); Days 1-7, 15-21
Trial: NCT03535727
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PO BID; Days 1- 14
Trial: NCT00027846
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
Trial: NCT01401179
Drug: cefazolin, erythromycin, clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
Trial: NCT03308799
Drug: MC2-01 cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
Trial: NCT03308799
Drug: Cal/BDP combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
Trial: NCT03067467
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.